---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-24-000025"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2024-02-12T23:59:59+00:00"
generated_at: "2026-06-06T04:23:06.550972+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports Q3 net loss $51.4M; plans 4-5 registrational trials for IMVT-1402

## Summary
- Net loss of $51.4M ($0.36/share) vs $63.2M ($0.49) a year ago; cash & equivalents $691M.
- IMVT-1402 Phase 1 showed 74% IgG reduction with no/minimal albumin or LDL changes vs placebo.
- Plans to start 4-5 potentially registrational IMVT-1402 programs by Mar 2025, 10 indications by Mar 2026.
- Batoclimab Phase 3 MG data expected 2H 2024; TED data 1H 2025; Phase 2b CIDP data 2Q/3Q 2024.
- R&D spend $48.3M in Q3, up from $42.3M, driven by IMVT-1402 development costs.

## SEC filing metadata
- accession: 0001764013-24-000025
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2024-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/imvt-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-24-000025
- JSON: https://secwatch.observer/filing/0001764013-24-000025.json
- Plain text: https://secwatch.observer/filing/0001764013-24-000025.txt

## Key facts
- Earnings Releases
  Immunovant, Inc. reported the fiscal third quarter ended December 31, 2023 results: net income Net loss was $51.4 million ($0.36 per common share), EPS $0.36 per common share.
  - Period: the fiscal third quarter ended December 31, 2023
  - Net income: Net loss was $51.4 million ($0.36 per common share)
  - EPS: $0.36 per common share
  - Result: reported results
  source text: Net loss was $51.4 million ($0.36 per common share) for the three months ended December 31, 2023, compared to $63.2 million ($0.49 per common share) for the three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm
- Earnings Releases
  Immunovant, Inc. reported the fiscal nine months ended December 31, 2023 results: net income Net loss was $184.0 million ($1.36 per common share), EPS $1.36 per common share.
  - Period: the fiscal nine months ended December 31, 2023
  - Net income: Net loss was $184.0 million ($1.36 per common share)
  - EPS: $1.36 per common share
  - Result: reported results
  source text: Net loss was $184.0 million ($1.36 per common share) for the nine months ended December 31, 2023, compared to $151.5 million ($1.26 per common share) for the nine months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1764013/000176401324000025/0001764013-24-000025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.